Skip to content

Safety and efficacy of potentised forms of cisplatin and docetaxel

Phase II study to assess safety & efficacy of using potentised (tautopathy) form of chemotherapy.

Status
Active, not recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/05/025045
Enrollment
30
Registered
2020-05-06
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-D49- Neoplasms

Interventions

Intervention1: Potentised form of Cisplatin (1C): Potentised chemotherepay agent Intervention2: Potentised form of Docetaxel (1C): Potentised chemotherepay agent

Sponsors

Central Council for Research in Homoeopathy
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Pre-diagnosed cases of cancer advised to undergo/undergoing chemotherapy with either cisplatin and/or Docetaxel. 2 Any age group 18 years or above; willing to give written informed consent for participation.

Exclusion criteria

Exclusion criteria: Patients having chemotherapy with drugs other than cisplatin and docetaxel.

Design outcomes

Primary

MeasureTime frame
Change in CTCAE grading and Naranjo ADR score of various components of ADR, every two weeks, physically or telephonically, or as the case may be depending on the next chemotherapy session.Timepoint: Decline in CTCAE grading and Naranjo ADR score of various components of ADR, every two weeks, physically or telephonically, or as the case may be depending on the next chemotherapy session.

Secondary

MeasureTime frame
Adherence to chemotherapy regimen, as prescribed by consulting oncologist for at least six months, or for the entire duration of chemotherapy as planned, whichever is earlier.Timepoint: Completion of chemotherapy regimen, as prescribed by consulting oncologist for at least six months, or for the entire duration of chemotherapy as planned, whichever is earlier.

Countries

India

Contacts

Public ContactDr Harleen Kaur

Apollo Hospitals, Chennai

sivajags@gmail.com07299911717

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 27, 2026